Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals and keeping the price target at $600.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to both Vertex’s core business and its future pipeline. He believes the new suicidality warning on ivacaftor-containing cystic fibrosis therapies will create only short-term share pressure, as physicians are expected to maintain current prescribing given the life-saving benefit and lack of comparable alternatives.
Seigerman further argues that Vertex’s dominant position in the cystic fibrosis market remains intact and continues to generate a robust, durable cash flow base that can fund innovation. He highlights recent positive developments for non-opioid pain candidate VX-548 and kidney disease program VX-147, alongside promising early data for VX-880 in type 1 diabetes, as evidence that pipeline progress supports additional upside in the stock.
In another report released yesterday, TipRanks – Google also reiterated a Buy rating on the stock with a $498.00 price target.